The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

Start Date01 Jul 2020

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

100 Clinical Results associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

100 Translational Medicine associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

100 Patents (Medical) associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

1,447

Literatures (Medical) associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

01 Nov 2024·Protoplasma

Chemically induced phenotype plasticity in the unicellular zygnematophyte, Penium margaritaceum

Article

Author: Tomasi, Tawn ; Sgambettera, Gabriel ; Domozych, David S ; Lu, Iris ; Bagdan, Kaylee ; LoRicco, Josephine G ; Malone, Stuart

AbstractPhenotypic plasticity allows a plant cell to alter its structure and function in response to external pressure. This adaptive phenomenon has also been important in the evolution of plants including the emergence of land plants from a streptophyte alga. Penium margaritaceum is a unicellular zygnematophyte (i.e., the group of streptophyte algae that is sister to land plants) that was employed in order to study phenotypic plasticity with a focus on the role of subcellular expansion centers and the cell wall in this process. Live cell fluorescence labeling, immunofluorescence labeling, transmission electron microscopy, and scanning electron microscopy showed significant subcellular changes and alterations to the cell wall. When treated with the actin-perturbing agent, cytochalasin E, cytokinesis is arrested and cells are transformed into pseudo-filaments made of up to eight or more cellular units. When treated with the cyclin-dependent kinase (CDK) inhibitor, roscovitine, cells converted to a unique phenotype with a narrow isthmus zone.

01 Sep 2024·Free Radical Research

Reduction of oxidative damage in prostate tissue caused by radiation and/or chloroquine by apocynin

Article

Author: Ertik, Onur ; Us, Huseyin ; Sezen Us, Ayca ; Coremen, Melis ; Yanardag, Refiye ; Karabulut Bulan, Omur ; Gul, Ilknur Bugan

Prostate damage can occur in men due to age and genetic factors, especially when exposed to external factors. Radiation (RAD) is a prominent factor leading to oxidative stress and potential prostate damage. Additionally, chloroquine (CQ), used in malaria treatment, can induce oxidative stress in a dose-dependent manner. Therefore, reducing and preventing oxidative damage in prostate tissue caused by external factors is crucial. Rats used in the study were divided into seven groups, CQ, apocynin (APO), RAD, CQ + APO, CQ + RAD, APO + RAD, CQ + APO + RAD. Subsequently, in vivo biochemical parameters of prostate tissues were examined, including reduced glutathione, lipid peroxidation, superoxide dismutase, glutathione reductase, glutathione peroxidase, glutathione-S-transferase activities, and total antioxidant status, total oxidant status, reactive oxygen species, oxidative stress index, advanced oxidation protein products and histologically. The in vivo results presented in our study showed that APO reduced oxidative stress and had a protective effect on prostate tissue in the CQ, RAD, and CQ + RAD groups as a results of biochemical and histological experiments. Additionally, in silico studies revealed a higher binding affinity of diapocynin to target proteins compared to APO. As a histological results, RAD and CQ alone or in combination did not induce damage in prostate tissues, whereas mild histopathological findings such as hyperemia and haemorrhage were observed in all APO-treated groups. The results suggest that the use of APO for the treatment of oxidative damage induced by CQ and RAD in rats.

03 Jul 2024·Future Cardiology

Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases

Article

Author: Molloy, Ashley ; Merlocco, Anthony ; Johnson, Jason ; Sathanandam, Shyam ; Naik, Ronak ; Absi, Mohammed ; Swaminathan, Nithya ; Tailor, Neil

Aim: The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.Methods: Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.Results: The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.Conclusion: The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.

100 Deals associated with Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperlipidemias	Phase 1	US	-	-
Kaposi Sarcoma	Phase 1	US	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAIC2019	Not Applicable	Dementia	-	APOLIPOPROTEIN E (ApoE in HDL that lacks apoC3)	cwuorzpksi(qxgolceevi): P-Value = 0.67 View more	-	01 Jul 2019
				APOLIPOPROTEIN E (ApoE in HDL that contains apoC3)
AAIC2016	Not Applicable	Dementia	809	Apolipoprotein E (homozygous E4 carriers)	sbhabnuxch(xswvarkpmx) = mrkzellqxf gyeyzncyrk (ecyefxvmzm )	-	01 Jul 2016
				Apolipoprotein E (heterozygous E4 carriers)	sbhabnuxch(xswvarkpmx) = lipvewyulm gyeyzncyrk (ecyefxvmzm )
EULAR2016	Not Applicable	Apo E	-	APOLIPOPROTEIN E	qrakatbeek(bkubkifvbz) = erijzpuxww wmzbhyxhow (luqpairrlg ) View more	-	08 Jun 2016
EULAR2010	Not Applicable	Fractures, Bone Apolipoprotein E	-	APOLIPOPROTEIN E	(yqwrdxymsy) = jirusscoim ajdtupbdgb (wggzquvecm ) View more	-	16 Jun 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Apolipoprotein E(Centre Hospitalier Universitaire de Nimes)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation